According to the latest issue of Cancer Prevention Research, a new drug being tested by Michigan State University scientists may prevent obesity-related genes from triggering breast cancer and lung cancer and prevent the development of these cancers. A preclinical study led by Karen Libby, an associate professor of pharmacology and toxicology at Michigan State University, showed that I-BET-762 drugs significantly slowed the development of breast and lung cancer by regulating the cancer gene C-Myc. Libby said that I-BET-762 acts by targeting DNA, making the gene unable to be expressed. It ultimately reduces the number of experimental mouse cancer cells by 80% by inhibiting many important proteins in cancer and immune cells. The importance of these proteins is reflected in their role in cell-cell interactions. For example, a specific protein called pSTAT3 can be activated in immune cells and prevent immune cells from fighting invading cancer. This harmful protein may also be overproduced in cancer cells and act as a barrier to ultimately protect the tumor. Studies have shown that the new drug reduces pSTAT3 levels in both cells by 50%. Another study led by Jamie Bennard, an assistant professor of pharmacology and toxicology at Michigan State University, applies Libby's findings to precancerous cells. By directly observing the effects of I-BET-762 on human cells that are not cancerous but have the potential to become cancerous, they found that new drugs prevented more than half of these cells from becoming cancerous. The C-Myc gene is induced by visceral fat, which is located around the internal organs of the body. Benard said nearly half a million new cancer cases are related to obesity. There is evidence that visceral fat and a high-fat diet increase the risk of cancer. Although current cancer treatments help reduce cancer mortality, the number of cancers associated with obesity continues to rise. According to Bernard, new prevention methods are urgently needed because of the limited effectiveness in reducing the high mortality rates of breast and lung cancer. New drugs similar to I-BET-762 are undergoing clinical trials for the treatment of various other cancers such as leukemia, lymphoma, brain tumors and myeloma. Researchers believe that new I-BET-762 drugs will increase survival opportunities for breast and lung cancer patients. (Technology Daily) Butterfly bean flower is also known as butterfly bean flower, blue butterfly flower, blue butterfly, butterfly blue flower, and other aliases such as butterfly sheep bean and bean bee. Its petals can be used for dyeing and eating, and are rich in vitamins A, C and E. It is rich in anthocyanins, which can improve immunity, help and promote skin elasticity and collagen production, and has antioxidant effects. Butterfly Pudding Powder,Blue Pigment,Butterfly Pea Flower Powder,Butterfly Pea Pollen Shaanxi Zhongyi Kangjian Biotechnology Co.,Ltd , https://www.zhongyibiology.com